Biogen (NASDAQ:BIIB), which is best known for its multiple sclerosis therapy franchise, will be spinning off Bioverativ (Pending:BIVV) on February 1, 2017. On January 6 Bioverativ executives gave an extensive presentation on the new company that should give investors a good idea of whether they want BIVV to be part of their portfolio.
Bioverativ will start with Biogen's hemophilia therapies and $325 million in cash. The therapies are Alprolix for hemophilia B and Eloctate for hemophilia A. Both therapies were introduced relatively recently and so have many years of exclusivity before they go generic. Bioverativ should report positive earnings from the beginning. Best of all, it is already planning on expanding to other blood diseases beyond hemophilia.

